Moderna, Inc.

Organisation

325 Binney Street, Cambridge, MA, United States, 02142

Headquarters

4700

Employees

Health Technology

Industry

Stephane Bancel

Moderna is a pharmaceutical and biotechnological company founded in 2010 in Massachusetts, the United States, by 'Derrick Rossi', 'Timothy A. Springer', 'Robert S. Langer', 'Kenneth R. Chien', 'Noubar Afeyan'. The CEO of this company is Stephan Bancel.
The company aims to provide primarily mRNA vaccines and RNA therapeutics. They use a copy of messenger RNA to create vaccines for immune response in a body. The company develops and discovers drugs capable of producing antibodies in the patient's cells.

The company develops and produces human proteins, antibodies, and novel proteins using mRNA therapeutics, which helps prevent, treat, and cure disease. The only commercial product of this company right now is the Moderna COVID-19 vaccine.
The Moderna Company has about twenty-three treatments and vaccine aspirants; fifteen have already been moved into the clinical trials. These vaccine aspirants consist of respiratory virus, chikungunya, single-shot COVID-19 booster, and many more.

The company's therapeutic areas are infectious diseases, immuno-oncology, rare diseases, cardiovascular disease, and auto-immune disease. The company's revenue is $803.4 million, and the company's capitalisation, including cash equivalents and investments, is $12.2 billion.

The company is currently developing clinical programs to create mRNA medicines for various diseases and conditions. They have made significant advancements in pioneering new vaccines and therapeutics that are capable of treating rare diseases MMA (Methylmalonic Acidemia) and PA (Propionic Acidemia) and preventing diseases like CMV (cytomegalovirus), Zika, and cancer. The company currently has twenty-three development programs and fifteen centred clinical studies.

The company has developed relations with several pharmaceutical and biotechnological companies, government organisations, foundations and research institutions with experience and knowledge to fuel the project. Some of the notable companies in the Moderna portfolio include 'AstraZeneca', 'Merck', 'Vertex', 'Barda', 'Bill and Melinda Gates', 'Darpa', 'Institut Pasteur', and 'Karolinska'.

Currently Moderna, Inc. has a market cap of $29.83 Billion. It has a P.E ratio of -5.08. The shares of Moderna, Inc. are trading at $49.56.
 .

Price

Target

Moderna, Inc. (MRNA) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Moderna, Inc. (MRNA) share price will touch around $43.75 in next 12-months.

Currently 31 wall-street analysts regularly analyze the financials of Moderna, Inc. on a frequent basis to provide recommendations along with target share price. 31 analysts offering 12-month price forecasts for Moderna, Inc. (MRNA) have a share price target of $43.75. This median of share price forecast represents a -11.79% downside from the latest price of $49.6 as on 30.03.26.

Moderna, Inc. (MRNA) Share Price Forecast

Home

US Stocks

Moderna, Inc. (MRNA)

Moderna, Inc. Stock Forecast

Moderna, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Moderna, Inc. (MRNA): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Moderna, Inc.'s share price and its median forecast price. As on 30.03.26, the difference is -34.26%

Moderna, Inc. Forecast and Target Price

Moderna, Inc. (MRNA) Share Price Forecast

Moderna, Inc. (MRNA) Price vs Consensus Price Target

Moderna, Inc. (MRNA) Share Price Forecast v/s Share Price Today

Moderna, Inc. (MRNA): Difference between Current Price & Median Forecasted Price

Moderna, Inc. (MRNA) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price